Last reviewed · How we verify
HA filler
HA filler is a hyaluronic acid-based dermal filler that physically fills facial wrinkles and volume loss by integrating into the dermis.
HA filler is a hyaluronic acid-based dermal filler that physically fills facial wrinkles and volume loss by integrating into the dermis. Used for Facial wrinkles and folds (nasolabial folds, marionette lines), Facial volume loss and contour enhancement, Lip augmentation.
At a glance
| Generic name | HA filler |
|---|---|
| Sponsor | University of Pennsylvania |
| Drug class | Dermal filler |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Aesthetic Medicine |
| Phase | FDA-approved |
Mechanism of action
Hyaluronic acid (HA) is a naturally occurring polysaccharide that binds water molecules, providing hydration and volumization to the skin. When injected into the dermis, HA fillers restore lost volume, smooth wrinkles, and enhance facial contours through mechanical filling and water-binding properties. The filler gradually integrates with surrounding tissue and is metabolized over time, typically lasting 6–12 months depending on formulation and injection site.
Approved indications
- Facial wrinkles and folds (nasolabial folds, marionette lines)
- Facial volume loss and contour enhancement
- Lip augmentation
Common side effects
- Injection site reactions (redness, swelling, bruising)
- Tenderness or pain at injection site
- Nodules or granulomas
- Allergic reaction
- Infection
Key clinical trials
- A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Intense Strong (NA)
- Clinical Investigation on Lips Treated With HA-filler (NA)
- A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Voluma (NA)
- Effect of TXA on Reducing Bruising After Filler Injection (PHASE2)
- Real-Life Evaluation of the HA Dermal Filler ESTYME® LIFT (NA)
- A Prospective Evaluation of the Filler for Jaw Contouring (PHASE4)
- Hyaluronic Acid Filler Migration (NA)
- FARE Augmentation of Proximal Femoral Fractures With CaS/HA and Systemic ZA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HA filler CI brief — competitive landscape report
- HA filler updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI